Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6121225 | 0.90 | DRD2 (0.46) | NAMPTCKS1BSKP1SKP2KMT2A | |
| SCHEMBL19380845 | 0.88 | NAMPT (0.41) | NAMPTCKS1BSKP1SKP2KMT2A | |
| SCHEMBL19380850 | 0.87 | KMT2A (0.51) | NAMPTCKS1BSKP1SKP2KMT2A | |
| SCHEMBL32677525 | 0.86 | NAMPT (0.42) | NAMPTCKS1BSKP1SKP2KMT2A | |
| SCHEMBL21187202 | 0.86 | MAPT (0.43) | NAMPTCKS1BSKP1SKP2KMT2A | |
| SCHEMBL32677522 | 0.86 | NAMPT (0.42) | NAMPTCKS1BSKP1SKP2KMT2A | |
| SCHEMBL32677509 | 0.85 | KDM4D (0.42) | NAMPTCKS1BSKP1SKP2KMT2A | |
| SCHEMBL32677506 | 0.85 | KDM4D (0.42) | NAMPTCKS1BSKP1SKP2KMT2A | |
| SCHEMBL12321516 | 0.84 | DRD2 (0.48) | NAMPTCKS1BSKP1SKP2KMT2A | |
| SCHEMBL3707832 | 0.83 | DRD2 (0.49) | NAMPTCKS1BSKP1SKP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115304-A1 | BIOACTIVE CONJUGATES, PREPARATION METHOD AND USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2026-04-30 | — | — | US | disclosed |
| WO-2025072437-A1 | HETEROARYL COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ALPHINA THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-11311528-B2 | Oxo-tetrahydro-isoquinoline carboxylic acids as STING inhibitors | MERCK SHARP & DOHME CORP. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11311528-B2 | Oxo-tetrahydro-isoquinoline carboxylic acids as STING inhibitors | MERCK SHARP & DOHME CORP. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210052573-A1 | OXO-TETRAHYDRO-ISOQUINOLINE CARBOXYLIC ACIDS AS STING INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160031880-A1 | Nampt and Rock Inhibitors | ABBVIE INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2640698-A1 | NAMPT AND ROCK INHIBITORS | AbbVie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012067965-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | NAMPT, NNMT, NADK | NAMPT 1/4885CKS1B 1676/4885SKP1 2082/4885 |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | NAMPT 1/4885CKS1B 1303/4885SKP1 3909/4885 |
| US-11311528-B2 | Oxo-tetrahydro-isoquinoline carboxylic acids as STING inhibitors | STING1, MAVS, CGAS | NAMPT 1139/4885CKS1B 2875/4885SKP1 3173/4885 |
| US-20260115304-A1 | BIOACTIVE CONJUGATES, PREPARATION METHOD AND USE THEREOF | GUSB, PSMA6, CD44 | NAMPT 2522/4885CKS1B 1640/4885SKP1 4011/4885 |
| US-20210052573-A1 | OXO-TETRAHYDRO-ISOQUINOLINE CARBOXYLIC ACIDS AS STING INHIBITORS | STING1, MAVS, CGAS | NAMPT 1139/4885CKS1B 2875/4885SKP1 3173/4885 |
| US-20160031880-A1 | Nampt and Rock Inhibitors | NAMPT, NNMT, NME2 | NAMPT 1/4885CKS1B 1303/4885SKP1 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.